ESC 365 - Discussion - Cardiac contractility modulation (CCM) in HFrEF NYHA Class III patients.

HFA Premium Access

Discussion - Cardiac contractility modulation (CCM) in HFrEF NYHA Class III patients.

Session: Late breaking trial III - Innovative and device therapy

Topic: Device Therapy

Event: Heart Failure 2019

Congress Presentation

11 more presentations in this session

Reduction of Mitral Regurgitation in Patients with Heart Failure and Secondary Mitral Regurgitation: Relationship Between Baseline Biomarkers and Outcomes from the COAPT Trial

Speaker: Professor W. Abraham (Columbus, US)

Discussion - COAPT.

A first in human multi-center, open label, prospective study to evaluate the safety, usability and performance of the V-LAP system

Speaker: Professor W. Abraham (Columbus, US)

Discussion - A first in human multi-center, open label, prospective study to evaluate the safety, usability and performance of the V-LAP system.

Cardiac contractility modulation (CCM) in HFrEF NYHA Class III patients

Speaker: Professor D. Burkhoff (New York, US)

Access the full session

Late breaking trial III - Innovative and device therapy

Speakers: Professor W. Abraham, Professor W. Abraham, Professor D. Burkhoff

About the event

Heart Failure 2019

25 May - 28 May 2019

Sessions Presentations

Congress

ESC 365 is supported by